Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / AUTL - EMA grants PRIME tag to Autolus Therapeutics' AUTO1 in blood cancer

AUTL - EMA grants PRIME tag to Autolus Therapeutics' AUTO1 in blood cancer

Autolus Therapeutics plc
Autolus Therapeutics (AUTL) has received PRIority MEdicines ((PRIME)) designation from the EMA for AUTO1,currently being investigated in the ongoing FELIX Phase 1b/2 study in relapsed / refractory adult B-Acute Lymphocytic Leukemia.PRIME, akin to Breakthrough Therapy status in the U.S., provides for more intensive guidance on development and accelerated review of the market application.AUTO1 is a CD19 CAR T cell investigational therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell therapies.B-cell acute lymphoblastic leukemia is a cancer that affects "B lymphocytes" - white blood cells that grow in the soft center of bones, called marrow.AUTL shares up 2.4% premarket trading at $5.87.

For further details see:

EMA grants PRIME tag to Autolus Therapeutics' AUTO1 in blood cancer
Stock Information
Company Name: Autolus Therapeutics plc
Stock Symbol: AUTL
Market: NASDAQ
Website: autolus.com
Menu
AUTL AUTL Quote AUTL Short AUTL News AUTL Articles AUTL Message Board
Get AUTL Alerts

News, Short Squeeze, Breakout and More Instantly...